Alzchem delivered strong H1 2024 results, with sales up 3.3% and EBITDA up 41% year-over-year, driven by Specialty Chemicals. Net income nearly doubled, free cash flow surged, and the EBITDA outlook for 2024 was raised above €100M.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.